0.930
-0.020
(-2.11%)
Real-time:
9:33am BST
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 0.87 - 0.94 |
| 52 week | 0.60 - 2.30 |
| Open | 0.95 |
| Vol / Avg. | 970,300.00/6.10M |
| Mkt cap | 14.15M* |
| P/E | - |
| Div/yield | - |
| EPS | 0.00* |
| Shares | 1,521.54M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Apr 22, 2013
Sareum Holdings PLC at Biotechnology Industry Organization (BIO) International Convention
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -103.25% | -82.55% |
| Return on average equity | -124.43% | -95.94% |
| Employees | 2 | - |
| Carbon Disclosure Rating | - | - |
Address
Unit 2a Langford Arch, London Road, Pampisford
CAMBRIDGE, CB22 3FX
United Kingdom - Map
+44-1223-497700 (Phone)
+44-1223-497701 (Fax)
CAMBRIDGE, CB22 3FX
United Kingdom - Map
+44-1223-497700 (Phone)
+44-1223-497701 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Sareum Holdings plc (Sareum) is a United Kingdom-based holding company. The Company is a cancer drug discovery company. The Company, along with its subsidiaries, is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company focuses on developing therapies for cancer and auto-immune diseases. In August 2011, the most promising lead molecule from this programme was declared a candidate for pre-clinical development. Sareum Kinase Inhibitor Library (SKIL) is Sareum�s drug discovery technology platform that has produced the Company�s Aurora, VEGFR-3, ALK, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against additional kinase and other targets.
Officers and directors
| Tim J. Mitchell Ph.D. | Chief Executive Officer, Executive Director | |
| John C. Reader Ph.D. | Chief Scientific Officer, Executive Director | |
| Tony Bunn | Secretary | |
| Paul B Harper PhD | Non-Executive Independent Chairman of the Board |